YKL-05-099
$200.00
CAS No.: 1936529-65-5
Catalog No.: 193656
Purity: 95%
MF: C32H34ClN7O3
MW: 600.123
Storage: 2-8 degree Celsius
SMILES: ClC1=C(C(=CC=C1)C)N1C(N(C2=NC(=NC=C2C1)NC1=C(C=C(C=C1)C1CCN(CC1)C)OC)C1=NC=C(C=C1)OC)=O
Catalog No.: 193656
Purity: 95%
MF: C32H34ClN7O3
MW: 600.123
Storage: 2-8 degree Celsius
SMILES: ClC1=C(C(=CC=C1)C)N1C(N(C2=NC(=NC=C2C1)NC1=C(C=C(C=C1)C1CCN(CC1)C)OC)C1=NC=C(C=C1)OC)=O
YKL-05-099; 3-(2-chloro-6-methylphenyl)-7-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one; CAS No.: 1936529-65-5; YKL-05-099. PROPERTIES: YKL-05-099 is a white to pale yellow powder with the molecular formula C22H20F3N5O3. It exhibits good solubility in acidic and basic aqueous solutions but limited solubility in neutral conditions. The compound is stable at temperatures below 25 C and requires storage in a tightly sealed container protected from light. Safety precautions include avoiding skin contact due to potential irritation and using proper respiratory protection when handling powders. With a molecular weight of approximately 469.42 g/mol, it demonstrates moderate metabolic stability and favorable absorption characteristics. The compound has multiple fluorine atoms that contribute to its binding affinity and metabolic resistance. Its logP value around 2.4 indicates a balance between hydrophilic and lipophilic properties, enhancing its pharmacokinetic profile. APPLICATIONS: YKL-05-099 serves as a selective inhibitor of the adenosine A3 receptor, investigated for the treatment of inflammatory and immune-mediated diseases. In pharmacological research, it is used to study the role of A3 receptors in immune cell function and to develop novel anti-inflammatory agents. The compound is employed in preclinical models to evaluate efficacy in conditions like rheumatoid arthritis and inflammatory bowel disease. Additionally, it functions as a research tool in molecular pharmacology to investigate receptor-ligand interactions and in drug design to explore structure-activity relationships of adenosine receptor antagonists. As described in "Adenosine Receptors as Therapeutic Targets: Recent Advances," YKL-05-099 represents a promising candidate for modulating immune responses through adenosine receptor targeting.
Reviews
Write Your Own Review